US Immuno-Oncology Xchange
Philadelphia, March 14, 2018

Welcome to hubXchange’s US Immuno-Oncology Xchange 2018, bringing together executives from pharma and biotech as well as thought leaders from academia to address and find solutions to the key issues faced in developing immuno-oncology therapies.

Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.

Confirmed Facilitators include:

William Hearl, President & Chief Executive Officer, Immunomic Therapeutics
• Ramon Mohanlal, Executive Vice President & Chief Medical Officer, BeyondSpring Pharmaceuticals
• Robert Iannone, Senior Vice President, Head of Immuno-Oncology, Global Medicines Development, AstraZeneca
• Andres Guiterrez, Chief Medical Officer, Oncolytics Biotec
• Stefan Scherer, Vice President, Head Early Development Strategy & Innovation, Novartis
• Cristian Massacesi, Vice President, Asset Team Leader, Immuno-Oncology, Pfizer
• Teng Jin Ong, Vice President, Medical Affairs, Celgene
• Harry Raftopoulos, Vice President, Translational Medicine – Immuno-Oncology, Bayer
• Charles Sentman, Professor, Microbiology & Immunology, Dartmouth Medical School
• Cori Gorman, Vice President, Precision Medicine & Manufacturing, Agenus Bio
• Jeffrey Skolnik, Vice President, Clinical Development, Inovio Pharmaceuticals
• Abdel Halim, Vice President, Translational Medicine, Biomarkers & Diagnostics, Celldex Therapeutics
• Ildiko Csiki, Vice President, Clinical Development, Immuno-Oncology, Inovio Pharmaceuticals
• Maria Karasarides, Executive Director, Immuno-Oncology, Regeneron Pharmaceuticals
• Roopa Srinivasan, Senior Director, Head of Translational Research, Immuno-Oncology R&D, GlaxoSmithKline


Platinum Sponsor

Gold Sponsor

Silver Sponsors

Bronze Sponsors


Doubletree by Hilton, Philadelphia Airport
4509 Island Avenue, Philadelphia, PA 19153
TEL: +1-215-365-4150